Autolus Therapeutics to Participate in Investor Conferences Through April
02 April 2021 - 7:01AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that management will participate in
1x1’s at investor conferences through April 2021.
- April 6 and 8, 2021 - Wells
Fargo Annual Biotech Corporate Access
- April 14, 2021 - 20th
Annual Needham Virtual Healthcare Conference – As well as
1x1’s, the CEO and CFO will participate in a Fireside Chat at 10:15
AM ET. A webcast of the Fireside Chat will be available on the
investor relations section of the Company’s website at
Autolus.
- April 22, 2021 - Raymond
James Oncology Summit
- April 28, 2021 - Kempen
& Co. European Life Sciences: Gene, Cell, and RNA
Day
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Contact:
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2024 to May 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2023 to May 2024